Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Verona Pharma plc has announced its preliminary unaudited net product sales for ...

Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...

(MENAFN- GlobeNewsWire - Nasdaq) Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...